ACD Pharma

行业

植物保护, 渔业与水产养殖, 采后处理与加工, 种子与遗传育种, 兽医

主题

虾/鱼遗传育种与水产养殖技术, 生物农药与生物防治, 畜禽生产与遗传育种

角色

研究机构 — “…: linked with the Norwegian University of Life Sciences and their own bacteriophage laboratory in Lofoten. - F…”

为何属于生物经济

ACD Pharma 是挪威公司，开发和制造面向水产养殖的噬菌体基生物防治产品，并研究人类和兽医用途以对抗抗生素耐药性。

发现途径

[Rubric] Austria · phages; [Rubric] Denmark · phages; [Rubric] Finland · phages; [Rubric] Iceland · phages

尚未被列为已评级方案的供应商。

• 2025-02-11 Tydelig fotavtrykk på Norway Life Science 2025  – Legemiddelindustrien
  ACD Pharma presented as a pioneer in phage-based solutions, highlighting Custus—the world’s first bacteriophage product used in Norwegian salmon farming to combat Yersinia ruckeri—and noting that phage therapies for humans are mainly challenged by cost, not …
• 2025-08-20 Fiskehelseselskapene markerte seg på Aqua Nor – Legemiddelindustrien
  ACD Pharma had a presence at Aqua Nor alongside other LMIs members, likely hosting or participating in stands or activities over the three-day event.
• 2026-07-02 We're proud to announce that ACD has entered into a venture philanthropy agreement with Ultragenyx, committing $4 million to advance the clinical development of an investigational therapy for Creatine Transporter Deficiency (CTD).
  ACD Pharma (ACD) has forged a venture philanthropy agreement with Ultragenyx, committing $4 million to advance a CTD investigational therapy, marking the largest research investment in ACD’s history and a milestone for their Race for a Cure initiative.
• 2025-02-03 Terclara (MOB-015) is now being launched in Norway
  Moberg Pharma and Allderma announce Terclara (MOB-015) is being launched in Norway, following success in Sweden. The rollout relies on a new terbinafine supplier and begins with pharmacy deliveries in February, supported by targeted education and consumer …
• 2025-08-26 Calluna Pharma Announces Initiation of Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary Fibrosis
  Calluna Pharma (not ACD Pharma) announces progression of CAL101 for IPF, including initiation of Phase 2 AURORA with 150 patients across 50+ sites, and later announces full enrollment completed ahead of plan and FDA Orphan Drug designation for CAL101. If you …
• 2025-10-24 Pharmaceutical volumes and rates weaken this year as pressure grows - The Loadstar
  ACD Pharma remains a strong, above-2019 level market, but its rate premiums are weakening relative to general cargo due to supply-side capacity and investments in pharma. The market is increasingly concentrated among large forwarders (with ~70% share) while a …

股权与投资方 1

同类企业

Phagos · Phageguard · Micreos · Proteon Pharmaceuticals · PHAXIAM Therapeutics · NexaBiome · Pherecydes Pharma · Inteliphage